Tenax Therapeutics, Inc. (NASDAQ:TENX) Sees Significant Decline in Short Interest

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a large decrease in short interest in August. As of August 31st, there was short interest totalling 90,900 shares, a decrease of 21.6% from the August 15th total of 115,900 shares. Based on an average daily volume of 496,100 shares, the short-interest ratio is currently 0.2 days. Approximately 3.1% of the shares of the company are sold short.

Tenax Therapeutics Trading Up 3.3 %

Shares of TENX stock opened at $3.81 on Monday. The company’s fifty day simple moving average is $3.68 and its two-hundred day simple moving average is $3.66. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.99) by $0.16. On average, sell-side analysts forecast that Tenax Therapeutics will post -6.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tenax Therapeutics in a research note on Tuesday, September 10th. They set a “sell” rating for the company.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.